Diabetic Nephropathy: Review of Novel Experimental and Clinical Strategies | ||||
| Bulletin of Faculty of Pharmacy, Cairo University | ||||
| Article 3, Volume 57, Issue 2, December 2019, Page 127-136 PDF (288.16 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfpc.2019.101869 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Amal M. Mahfoz1, 2; Nahed M. Hassanein2; Afaf A. Shoka3; Hekma A. Abd El- Latif1, 3 | ||||
| 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.+ | ||||
| 2Department of Developmental Pharmacology, National Organization for Drug Control and Research (NODCAR), Giza, Egypt. | ||||
| 3Faculty of Pharmacy, Cairo University, Cairo, Egypt. | ||||
| Abstract | ||||
| Background: Diabetic nephropathy (DN) is considered a severe disorder which affects health worldwide. New more active treatment options are required. Despite a large number of drugs already being available for treatment of hyperglycemia in diabetes, current oral antidiabetic agents often do not provide adequate glycemic control. Renin-angiotensin-aldosterone system (RAAS) blockers are novel agents to slow the progression of DN. Method: The present review provides an overview of recent studies on DN management, especially the use RAAS blockers and their antidiabetic effects. References were mainly identified through PubMed search until December 2016 and backtracking of references in pertinent studies. Results: This review reporting the novel mechanisms and benefits of targeting the RAAS by the use of ACEIs; ARB or direct renin inhibitors in glucose lowering, antioxidant and anti-inflammatory effects and kidney protection. Conclusion: These drugs targeting the RAAS can be used as monotherapy or in combination therapy in hypertensive-diabetic patients to protect them from DN. | ||||
| Keywords | ||||
| ACEIs; aliskiren; diabetic nephropathy; RAAS | ||||
|
Statistics Article View: 463 PDF Download: 640 |
||||
